Pharma giant to study GSK if the best -selling ringworm reduces dementia risk
The British drug manufacturer is using some 1.4 million people’s health data, some of which received its shingrix shot and some were not done to check if it reduces dementia risk.
The GSK said on Tuesday that he is studying a group of more than one lakh old adults in the UK to check if its best -selling shingles reduce the risk of vaccine dementia.
The British drug manufacturer is using health data of some 1.4 million people between the ages of 65 and 66, some of which received its shingrix shot and some who did not.
GSK Chief Scientific Officer Tony Wood said that the state -run National Health Services (NHS) is a unique set of data from the large database, as the UK Shingles vaccination program effectively is a naturally a random test due to a twist that is already happening.
When the National Vaccine program expanded in 2023, the 65 -year -old children became eligible for the shingrix vaccine, while the first 70 years and older people were eligible. However, at the time of expansion, people aged 66 and above were informed that they could not find it until they became 70. This meant that two big patient groups were assigned randomly to different vaccination groups.
It would be “prohibitively expensive” to run tests on such a large group, Wood said on a media call. “So this is a partnership that allows us to answer a question that cannot actually imagine answering under normal circumstances.”
The study will check the data until the 66-year children become 70 years old and do not become eligible for the vaccine, taking into account other medical conditions.
Research has already shown that vaccines against viral infections potentially reduce the risk of dementia, but previous studies have only identified identified associations, not tasks -causes.
New study in partnership with UK Dementia Research Institute and Health Data Research UK will definitely assess the question more. If confirmed, GSK can discuss data with regulators in the hope of achieving an extended label for JAB.
More than 55 million people globally have dementia. The field of research of Alzheimer’s was filled with failures for decades, but now many clinical trials for a group of Alzheimer’s vaccines are undergoing or being completed, which can eventually lead to success therapy.
